Abstract:Purpose: To investigate the effects of different anti-VEGF drugs on fibrovascular membranes (FVM) in proliferative diabetic retinopathy (PDR). In addition, in vitro model was used to simulate the intraocular fibroblasts barrier to explore the penetration of different anti-VEGF drugs. Methods: 24 eyes from 24 PDR patients with FVM were recruited for this prospective observational study. The patients were randomized to receive one of three anti-VEGF drugs (Ranibizumab, Conbercept, or Aflibercept). Then neovascular structures were assessed by optical coherence tomography angiography (OCTA) before intravitreal injection (pre-IVT) and 1, 2, and 3 days after intravitreal injection (post-IVT). The changes in vessels area (VSA), vessels percentage area (VPA), junction density (JD), and average lacunarity (AL) were analyzed by using the image processing software Angiotool. In vitro penetrating model with fibroblasts barrier was used to compare the effects of the three drugs on human retinal vascular endothelial cells (HRVECs) over 3 days by Cell proliferation measurement. Moreover, the drug concentrations in the penetrating model were detected by liquid chromatography-mass spectrometry (LC-MS). Results: The VSA, VPA, and JD all decreased, while the AL increased in Ranibizumab group(n = 8), Conbercept group (n = 8), and Aflibercept group (n = 8) within 3 days (P<0.05). Meanwhile, under the condition of the same amount of substance, the inhibition effect of Ranibizumab on HRVEC was the strongest in the penetrating model evaluated by CCK8 absorbance experiments of HRVECs (FCCK8=6.493, PCCK8= 0.0051), and the number of transmembrane molecules in the Ranibizumab group was also the largest within 3 days (F = 8.209, P = 0.0006) among the three groups. Conclusion: Angiotool is feasible to reconstruct the neovascular structure on the FVM in OCTA images. The three different anti-VEGF drugs can significantly reduce the vascular area and density on the proliferating membranes, and there is no significant difference in the anti-neovascularization among the three drugs clinically. However, small molecule drug is more penetrating and move faster across membranes in vitro cell model. Clinical trial registration: This trial is registered with the Chinese Clinical Trial Registry (http://www.chictr.org.cn, registration number ChiCTR2300067476).

The Relationship Between Anti-Vascular Endothelial Growth Factor and Fibrosis in Proliferative Retinopathy: Clinical and Laboratory Evidence

Changes in Vitreous VEGF, Bfgf and Fibrosis in Proliferative Diabetic Retinopathy after Intravitreal Bevacizumab.

Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.

Preoperative Timing of Intravitreal Bevacizumab Injection for Proliferative Diabetic Retinopathy Patients

Effects of Bevacizumab on CTGF and PEDF in Proliferative Membrane in Patients with PDR

Short Term Effect of Pre-Operative Anti-VEGF on Angiogenic and Fibrotic Profile of Fibrovascular Membranes of Proliferative Diabetic Retinopathy

Effect of Intravitreal Injection with Bevacizumab on Expression of Integrin-Linked Kinase in Fibrovascular Membranes of Proliferative Diabetic Retinopathy

Vitreous Fibronectin and Fibrinogen Expression Increased in Eyes with Proliferative Diabetic Retinopathy after Intravitreal Anti-VEGF Therapy

Effect of Intravitreal Ranibizumab on Fibrovascular Membranes in Patients with Proliferative Diabetic Retinopathy.

Study on the effects of different anti-VEGF drugs on fibrovascular membranes of proliferative diabetic retinopathy

Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy.

Comprehensive Assessment of Growth Factors, Inflammatory Mediators, and Cytokines in Vitreous from Patients with Proliferative Diabetic Retinopathy.

Change of Vascular Endothelial Growth Factor Levels Following Vitrectomy in Eyes with Proliferative Diabetic Retinopathy

Inhibition of Neovascularization and Expression Shift of Pro-/Anti-Angiogenic Vascular Endothelial Growth Factor Isoforms after Intravitreal Bevacizumab Injection in Oxygen-Induced-Retinopathy Mouse Model

Effect of anti-vascular endothelial growth factor on early-stage post-vitrectomy macular edema in patients with proliferative diabetic retinopathy

Reduced Expression of Erythropoietin After Intravitreal Ranibizumab in Proliferative Diabetic Retinopathy Patients—Retrospective Interventional Study

Apelin in epiretinal membranes of patients with proliferative diabetic retinopathy.

Anti-Vascular Endothelial Growth Factor Therapy as an Adjunct to Diabetic Vitrectomy

Study on Vascular Endothelial Growth Factor and Pigment Epithelium-derived Factor in Vitreous of Diabetic Retinopathy

Vascular endothelial growth factor/connective tissue growth factor and proteomic analysis of aqueous humor after intravitreal conbercept for proliferative diabetes retinopathy

Effect of an intravitreal injection of bevacizumab on the expression of VEGF and CD34 in the retina of diabetic rats: Bevacizumab a retinal anti-angiogenesis